Skip to main content
Top
Published in: Nutrition & Metabolism 1/2008

Open Access 01-12-2008 | Research

Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial

Authors: Robert H Lerman, Deanna M Minich, Gary Darland, Joseph J Lamb, Barbara Schiltz, John G Babish, Jeffrey S Bland, Matthew L Tripp

Published in: Nutrition & Metabolism | Issue 1/2008

Login to get access

Abstract

Background

As the worldwide dietary pattern becomes more westernized, the metabolic syndrome is reaching epidemic proportions. Lifestyle modifications including diet and exercise are recommended as first-line intervention for treating metabolic syndrome. Previously, we reported that a modified Mediterranean-style, low glycemic load diet with soy protein and phytosterols had a more favorable impact than the American Heart Association Step 1 diet on cardiovascular disease (CVD) risk factors. Subsequently, we screened for phytochemicals with a history of safe use that were capable of increasing insulin sensitivity through modulation of protein kinases, and identified hops rho iso-alpha acid and acacia proanthocyanidins. The objective of this study was to investigate whether enhancement of a modified Mediterranean-style, low glycemic load diet (MED) with specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED) could improve cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia.

Methods

Forty-nine subjects with metabolic syndrome and hypercholesterolemia, aged 25–80, entered a randomized, 2-arm, 12-week intervention trial; 23 randomized to the MED arm; 26 to the PED arm. Forty-four subjects completed at least 8 weeks [MED (n = 19); PED (n = 25)]. All subjects were instructed to follow the same aerobic exercise program. Three-day diet diaries and 7-day exercise diaries were assessed at each visit. Fasting blood samples were collected at baseline, 8 and 12 weeks for analysis.

Results

Both arms experienced equal weight loss (MED: -5.7 kg; PED: -5.9 kg). However, at 12 weeks, the PED arm experienced greater reductions (P < 0.05) in cholesterol, non-HDL cholesterol, triglycerides (TG), cholesterol/HDL and TG/HDL compared with the MED arm. Only the PED arm experienced increased HDL (P < 0.05) and decreased TG/HDL (P < 0.01), and continued reduction in apo B/apo A-I from 8 to 12 weeks. Furthermore, 43% of PED subjects vs. only 22% of MED subjects had net resolution of metabolic syndrome. The Framingham 10-year CVD risk score decreased by 5.6% in the PED arm (P < 0.01) and 2.9% in the MED arm (P < 0.05).

Conclusion

These results demonstrate that specific phytochemical supplementation increased the effectiveness of the modified Mediterranean-style low glycemic load dietary program on variables associated with metabolic syndrome and CVD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fito M, Guxens M, Corella D, Saez G, Estruch R, de la Torre R, Frances F, Cabezas C, Lopez-Sabater Mdel C, Marrugat J, Garcia-Arellano A, Aros F, Ruiz-Gutierrez V, Ros E, Salas-Salvado J, Fiol M, Sola R, Covas MI: Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. Arch Intern Med 2007, 167: 1195-1203.CrossRef Fito M, Guxens M, Corella D, Saez G, Estruch R, de la Torre R, Frances F, Cabezas C, Lopez-Sabater Mdel C, Marrugat J, Garcia-Arellano A, Aros F, Ruiz-Gutierrez V, Ros E, Salas-Salvado J, Fiol M, Sola R, Covas MI: Effect of a traditional Mediterranean diet on lipoprotein oxidation: a randomized controlled trial. Arch Intern Med 2007, 167: 1195-1203.CrossRef
2.
go back to reference Mitrou PN, Kipnis V, Thiebaut AC, Reedy J, Subar AF, Wirfalt E, Flood A, Mouw T, Hollenbeck AR, Leitzmann MF, Schatzkin A: Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med 2007, 167: 2461-2468.CrossRef Mitrou PN, Kipnis V, Thiebaut AC, Reedy J, Subar AF, Wirfalt E, Flood A, Mouw T, Hollenbeck AR, Leitzmann MF, Schatzkin A: Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study. Arch Intern Med 2007, 167: 2461-2468.CrossRef
3.
go back to reference O'Keefe JH, Bell DS: Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007, 100: 899-904.CrossRef O'Keefe JH, Bell DS: Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007, 100: 899-904.CrossRef
4.
go back to reference Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365: 1415-1428.CrossRef Eckel RH, Grundy SM, Zimmet PZ: The metabolic syndrome. Lancet 2005, 365: 1415-1428.CrossRef
5.
go back to reference Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005, 56: 45-62.CrossRef Moller DE, Kaufman KD: Metabolic syndrome: a clinical and molecular perspective. Annu Rev Med 2005, 56: 45-62.CrossRef
6.
go back to reference Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28: 2745-2749.CrossRef Ford ES: Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005, 28: 2745-2749.CrossRef
7.
go back to reference Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F: Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther 2007, 82: 509-524.CrossRef Batsis JA, Nieto-Martinez RE, Lopez-Jimenez F: Metabolic syndrome: from global epidemiology to individualized medicine. Clin Pharmacol Ther 2007, 82: 509-524.CrossRef
8.
go back to reference Day C: Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res 2007, 4: 32-38.CrossRef Day C: Metabolic syndrome, or What you will: definitions and epidemiology. Diab Vasc Dis Res 2007, 4: 32-38.CrossRef
9.
go back to reference Forsythe CE, Phinney SD, Fernandez ML, Quann EE, Wood RJ, Bibus DM, Kraemer WJ, Feinman RD, Volek JS: Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids 2008, 43: 65-77.CrossRef Forsythe CE, Phinney SD, Fernandez ML, Quann EE, Wood RJ, Bibus DM, Kraemer WJ, Feinman RD, Volek JS: Comparison of low fat and low carbohydrate diets on circulating fatty acid composition and markers of inflammation. Lipids 2008, 43: 65-77.CrossRef
10.
go back to reference Volek JS, Feinman RD: Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction. Nutr Metab (Lond) 2005, 2: 31.CrossRef Volek JS, Feinman RD: Carbohydrate restriction improves the features of Metabolic Syndrome. Metabolic Syndrome may be defined by the response to carbohydrate restriction. Nutr Metab (Lond) 2005, 2: 31.CrossRef
11.
go back to reference Volek JS, Fernandez ML, Feinman RD, Phinney SD: Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res 2008, 47: 307-318.CrossRef Volek JS, Fernandez ML, Feinman RD, Phinney SD: Dietary carbohydrate restriction induces a unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. Prog Lipid Res 2008, 47: 307-318.CrossRef
12.
go back to reference Riccardi G, Giacco R, Rivellese AA: Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 2004, 23: 447-456.CrossRef Riccardi G, Giacco R, Rivellese AA: Dietary fat, insulin sensitivity and the metabolic syndrome. Clin Nutr 2004, 23: 447-456.CrossRef
13.
go back to reference Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25: 4-7.CrossRef Dandona P, Aljada A, Bandyopadhyay A: Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25: 4-7.CrossRef
14.
go back to reference McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51: 7-18.CrossRef McGarry JD: Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002, 51: 7-18.CrossRef
15.
go back to reference Slawik M, Vidal-Puig AJ: Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev 2006, 5: 144-164.CrossRef Slawik M, Vidal-Puig AJ: Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev 2006, 5: 144-164.CrossRef
16.
go back to reference Boden G, Chen X, Rosner J, Barton M: Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995, 44: 1239-1242.CrossRef Boden G, Chen X, Rosner J, Barton M: Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995, 44: 1239-1242.CrossRef
17.
go back to reference Brechtel K, Dahl DB, Machann J, Bachmann OP, Wenzel I, Maier T, Claussen CD, Haring HU, Jacob S, Schick F: Fast elevation of the intramyocellular lipid content in the presence of circulating free fatty acids and hyperinsulinemia: a dynamic 1H-MRS study. Magn Reson Med 2001, 45: 179-183.CrossRef Brechtel K, Dahl DB, Machann J, Bachmann OP, Wenzel I, Maier T, Claussen CD, Haring HU, Jacob S, Schick F: Fast elevation of the intramyocellular lipid content in the presence of circulating free fatty acids and hyperinsulinemia: a dynamic 1H-MRS study. Magn Reson Med 2001, 45: 179-183.CrossRef
18.
go back to reference Kelley DE, Mintun MA, Watkins SC, Simoneau JA, Jadali F, Fredrickson A, Beattie J, Theriault R: The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 1996, 97: 2705-2713.CrossRef Kelley DE, Mintun MA, Watkins SC, Simoneau JA, Jadali F, Fredrickson A, Beattie J, Theriault R: The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest 1996, 97: 2705-2713.CrossRef
19.
go back to reference Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996, 97: 2859-2865.CrossRef Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI: Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996, 97: 2859-2865.CrossRef
20.
go back to reference Permana PA, Menge C, Reaven PD: Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 2006, 341: 507-514.CrossRef Permana PA, Menge C, Reaven PD: Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochem Biophys Res Commun 2006, 341: 507-514.CrossRef
21.
go back to reference Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112: 1796-1808.CrossRef Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112: 1796-1808.CrossRef
22.
go back to reference Patiag D, Gray S, Idris I, Donnelly R: Effects of tumour necrosis factor-alpha and inhibition of protein kinase C on glucose uptake in L6 myoblasts. Clin Sci (Lond) 2000, 99: 303-307.CrossRef Patiag D, Gray S, Idris I, Donnelly R: Effects of tumour necrosis factor-alpha and inhibition of protein kinase C on glucose uptake in L6 myoblasts. Clin Sci (Lond) 2000, 99: 303-307.CrossRef
23.
go back to reference Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK: Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005, 54: 2939-2945.CrossRef Plomgaard P, Bouzakri K, Krogh-Madsen R, Mittendorfer B, Zierath JR, Pedersen BK: Tumor necrosis factor-alpha induces skeletal muscle insulin resistance in healthy human subjects via inhibition of Akt substrate 160 phosphorylation. Diabetes 2005, 54: 2939-2945.CrossRef
24.
go back to reference Ranganathan S, Davidson MB: Effect of tumor necrosis factor-alpha on basal and insulin-stimulated glucose transport in cultured muscle and fat cells. Metabolism 1996, 45: 1089-1094.CrossRef Ranganathan S, Davidson MB: Effect of tumor necrosis factor-alpha on basal and insulin-stimulated glucose transport in cultured muscle and fat cells. Metabolism 1996, 45: 1089-1094.CrossRef
25.
go back to reference Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS: A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med 2003, 157: 773-779.CrossRef Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS: A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med 2003, 157: 773-779.CrossRef
26.
go back to reference Ebbeling CB, Leidig MM, Sinclair KB, Seger-Shippee LG, Feldman HA, Ludwig DS: Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. Am J Clin Nutr 2005, 81: 976-982. Ebbeling CB, Leidig MM, Sinclair KB, Seger-Shippee LG, Feldman HA, Ludwig DS: Effects of an ad libitum low-glycemic load diet on cardiovascular disease risk factors in obese young adults. Am J Clin Nutr 2005, 81: 976-982.
27.
go back to reference Maki KC, Rains TM, Kaden VN, Raneri KR, Davidson MH: Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. Am J Clin Nutr 2007, 85: 724-734. Maki KC, Rains TM, Kaden VN, Raneri KR, Davidson MH: Effects of a reduced-glycemic-load diet on body weight, body composition, and cardiovascular disease risk markers in overweight and obese adults. Am J Clin Nutr 2007, 85: 724-734.
28.
go back to reference Sloth B, Krog-Mikkelsen I, Flint A, Tetens I, Bjorck I, Vinoy S, Elmstahl H, Astrup A, Lang V, Raben A: No difference in body weight decrease between a low-glycemic-index and a high-glycemic-index diet but reduced LDL cholesterol after 10-wk ad libitum intake of the low-glycemic-index diet. Am J Clin Nutr 2004, 80: 337-347. Sloth B, Krog-Mikkelsen I, Flint A, Tetens I, Bjorck I, Vinoy S, Elmstahl H, Astrup A, Lang V, Raben A: No difference in body weight decrease between a low-glycemic-index and a high-glycemic-index diet but reduced LDL cholesterol after 10-wk ad libitum intake of the low-glycemic-index diet. Am J Clin Nutr 2004, 80: 337-347.
29.
go back to reference Giugliano D, Esposito K: Mediterranean diet and metabolic diseases. Curr Opin Lipidol 2008, 19: 63-68. Giugliano D, Esposito K: Mediterranean diet and metabolic diseases. Curr Opin Lipidol 2008, 19: 63-68.
30.
go back to reference Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) Jama 2001, 285: 2486-2497.CrossRef Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) Jama 2001, 285: 2486-2497.CrossRef
31.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112: 2735-2752.CrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112: 2735-2752.CrossRef
32.
go back to reference Giugliano D, Ceriello A, Esposito K: Are there specific treatments for the metabolic syndrome? Am J Clin Nutr 2008, 87: 8-11. Giugliano D, Ceriello A, Esposito K: Are there specific treatments for the metabolic syndrome? Am J Clin Nutr 2008, 87: 8-11.
33.
go back to reference O'Keefe JH, Gheewala NM, O'Keefe JO: Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008, 51: 249-255.CrossRef O'Keefe JH, Gheewala NM, O'Keefe JO: Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 2008, 51: 249-255.CrossRef
34.
go back to reference Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24: 935-942.CrossRef Lassila M, Allen TJ, Cao Z, Thallas V, Jandeleit-Dahm KA, Candido R, Cooper ME: Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24: 935-942.CrossRef
35.
go back to reference Lin JK: Molecular targets of curcumin. Adv Exp Med Biol 2007, 595: 227-243.CrossRef Lin JK: Molecular targets of curcumin. Adv Exp Med Biol 2007, 595: 227-243.CrossRef
36.
go back to reference Si H, Liu D: Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem 2007, 14: 2581-2589.CrossRef Si H, Liu D: Phytochemical genistein in the regulation of vascular function: new insights. Curr Med Chem 2007, 14: 2581-2589.CrossRef
37.
go back to reference Lukaczer D, Liska DJ, Lerman RH, Darland G, Schiltz B, Tripp M, Bland JS: Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. Nutrition 2006, 22: 104-113.CrossRef Lukaczer D, Liska DJ, Lerman RH, Darland G, Schiltz B, Tripp M, Bland JS: Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women. Nutrition 2006, 22: 104-113.CrossRef
38.
go back to reference Riccardi G, Clemente G, Giacco R: Glycemic index of local foods and diets: the Mediterranean experience. Nutr Rev 2003, 61: S56-60.CrossRef Riccardi G, Clemente G, Giacco R: Glycemic index of local foods and diets: the Mediterranean experience. Nutr Rev 2003, 61: S56-60.CrossRef
39.
go back to reference Foster-Powell K, Holt SH, Brand-Miller JC: International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 2002, 76: 5-56. Foster-Powell K, Holt SH, Brand-Miller JC: International table of glycemic index and glycemic load values: 2002. Am J Clin Nutr 2002, 76: 5-56.
40.
go back to reference Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473-483.CrossRef Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30: 473-483.CrossRef
41.
go back to reference White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG: Development and validation of the food-craving inventory. Obes Res 2002, 10: 107-114.CrossRef White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG: Development and validation of the food-craving inventory. Obes Res 2002, 10: 107-114.CrossRef
42.
go back to reference Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V: AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999, 34: 1348-1359.CrossRef Grundy SM, Pasternak R, Greenland P, Smith S Jr, Fuster V: AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999, 34: 1348-1359.CrossRef
43.
go back to reference Nauck M, Warnick GR, Rifai N: Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002, 48: 236-254. Nauck M, Warnick GR, Rifai N: Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. Clin Chem 2002, 48: 236-254.
44.
go back to reference Maki KC, Galant R, Davidson MH: Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol 2005, 96: 59K-64K.CrossRef Maki KC, Galant R, Davidson MH: Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol 2005, 96: 59K-64K.CrossRef
45.
go back to reference Anderson RA: Chromium and polyphenols from cinnamon improve insulin sensitivity. Proc Nutr Soc 2008, 67: 48-53.CrossRef Anderson RA: Chromium and polyphenols from cinnamon improve insulin sensitivity. Proc Nutr Soc 2008, 67: 48-53.CrossRef
46.
go back to reference Heilbronn LK, Noakes M, Clifton PM: The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. J Am Coll Nutr 2002, 21: 120-127.CrossRef Heilbronn LK, Noakes M, Clifton PM: The effect of high- and low-glycemic index energy restricted diets on plasma lipid and glucose profiles in type 2 diabetic subjects with varying glycemic control. J Am Coll Nutr 2002, 21: 120-127.CrossRef
47.
go back to reference Noakes M, Foster PR, Keogh JB, Clifton PM: Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome. J Nutr 2004, 134: 1894-1899. Noakes M, Foster PR, Keogh JB, Clifton PM: Meal replacements are as effective as structured weight-loss diets for treating obesity in adults with features of metabolic syndrome. J Nutr 2004, 134: 1894-1899.
48.
go back to reference De Keukeleire D: Fundamentals of beer and hop chemistry. Química Nova 2000, 23: 108-112.CrossRef De Keukeleire D: Fundamentals of beer and hop chemistry. Química Nova 2000, 23: 108-112.CrossRef
49.
go back to reference De Keukeleire D, De Cooman L, Rong H, Heyerick A, Kalita J, Milligan SR: Functional properties of hop polyphenols. Basic Life Sci 1999, 66: 739-760. De Keukeleire D, De Cooman L, Rong H, Heyerick A, Kalita J, Milligan SR: Functional properties of hop polyphenols. Basic Life Sci 1999, 66: 739-760.
50.
go back to reference Abd el Nabi OM, Reisinger EC, Reinthaler FF, Still F, Eibel U, Krejs GJ: Antimicrobial activity of Acacia nilotica (L.) Willd. ex Del. var. nilotica (Mimosaceae). J Ethnopharmacol 1992, 37: 77-79.CrossRef Abd el Nabi OM, Reisinger EC, Reinthaler FF, Still F, Eibel U, Krejs GJ: Antimicrobial activity of Acacia nilotica (L.) Willd. ex Del. var. nilotica (Mimosaceae). J Ethnopharmacol 1992, 37: 77-79.CrossRef
51.
go back to reference Al-Mustafa ZH, Dafallah AA: A study on the toxicology of Acacia nilotica. Am J Chin Med 2000, 28: 123-129.CrossRef Al-Mustafa ZH, Dafallah AA: A study on the toxicology of Acacia nilotica. Am J Chin Med 2000, 28: 123-129.CrossRef
52.
go back to reference Kaur K, Arora S, Hawthorne ME, Kaur S, Kumar S, Mehta RG: A correlative study on antimutagenic and chemopreventive activity of Acacia auriculiformis A. Cunn. and Acacia nilotica (L.) Willd. Ex Del. Drug Chem Toxicol 2002, 25: 39-64.CrossRef Kaur K, Arora S, Hawthorne ME, Kaur S, Kumar S, Mehta RG: A correlative study on antimutagenic and chemopreventive activity of Acacia auriculiformis A. Cunn. and Acacia nilotica (L.) Willd. Ex Del. Drug Chem Toxicol 2002, 25: 39-64.CrossRef
53.
go back to reference TR N: A Biology of Acacias. Melbourne, Oxford University Press; 1984. TR N: A Biology of Acacias. Melbourne, Oxford University Press; 1984.
54.
go back to reference Shimura M, Hasumi A, Minato T, Hosono M, Miura Y, Mizutani S, Kondo K, Oikawa S, Yoshida A: Isohumulones modulate blood lipid status through the activation of PPAR alpha. Biochim Biophys Acta 2005, 1736: 51-60. Shimura M, Hasumi A, Minato T, Hosono M, Miura Y, Mizutani S, Kondo K, Oikawa S, Yoshida A: Isohumulones modulate blood lipid status through the activation of PPAR alpha. Biochim Biophys Acta 2005, 1736: 51-60.
55.
go back to reference Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, Tsuboyama-Kasaoka N, Ezaki O, Oikawa S, Kondo K: Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. J Biol Chem 2004, 279: 33456-33462.CrossRef Yajima H, Ikeshima E, Shiraki M, Kanaya T, Fujiwara D, Odai H, Tsuboyama-Kasaoka N, Ezaki O, Oikawa S, Kondo K: Isohumulones, bitter acids derived from hops, activate both peroxisome proliferator-activated receptor alpha and gamma and reduce insulin resistance. J Biol Chem 2004, 279: 33456-33462.CrossRef
56.
go back to reference Jenkins DJ, Wolever TM, Kalmusky J, Guidici S, Giordano C, Patten R, Wong GS, Bird JN, Hall M, Buckley G, et al.: Low-glycemic index diet in hyperlipidemia: use of traditional starchy foods. Am J Clin Nutr 1987, 46: 66-71. Jenkins DJ, Wolever TM, Kalmusky J, Guidici S, Giordano C, Patten R, Wong GS, Bird JN, Hall M, Buckley G, et al.: Low-glycemic index diet in hyperlipidemia: use of traditional starchy foods. Am J Clin Nutr 1987, 46: 66-71.
57.
go back to reference Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D: Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. Jama 2004, 292: 1440-1446.CrossRef Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D: Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. Jama 2004, 292: 1440-1446.CrossRef
58.
go back to reference Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005, 142: 611-619.CrossRef Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S: The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med 2005, 142: 611-619.CrossRef
59.
go back to reference Ghandehari H, Kamal-Bahl S, Wong ND: Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 2008, 156: 112-119.CrossRef Ghandehari H, Kamal-Bahl S, Wong ND: Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003–2004. Am Heart J 2008, 156: 112-119.CrossRef
60.
go back to reference Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001, 161: 1413-1419.CrossRef Cui Y, Blumenthal RS, Flaws JA, Whiteman MK, Langenberg P, Bachorik PS, Bush TL: Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001, 161: 1413-1419.CrossRef
61.
go back to reference Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003, 26: 16-23.CrossRef Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, Robbins DC, Howard BV: Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care 2003, 26: 16-23.CrossRef
62.
go back to reference Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J: Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004, 110: 2824-2830.CrossRef Shai I, Rimm EB, Hankinson SE, Curhan G, Manson JE, Rifai N, Stampfer MJ, Ma J: Multivariate assessment of lipid parameters as predictors of coronary heart disease among postmenopausal women: potential implications for clinical guidelines. Circulation 2004, 110: 2824-2830.CrossRef
63.
go back to reference Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110: 227-239.CrossRef Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110: 227-239.CrossRef
64.
go back to reference Chan DC, Watts GF: Apolipoproteins as markers and managers of coronary risk. Qjm 2006, 99: 277-287.CrossRef Chan DC, Watts GF: Apolipoproteins as markers and managers of coronary risk. Qjm 2006, 99: 277-287.CrossRef
65.
go back to reference Hankey GJ: Potential new risk factors for ischemic stroke: what is their potential? Stroke 2006, 37: 2181-2188.CrossRef Hankey GJ: Potential new risk factors for ischemic stroke: what is their potential? Stroke 2006, 37: 2181-2188.CrossRef
66.
go back to reference Hoffstedt J, Forster D, Lofgren P: Impaired subcutaneous adipocyte lipogenesis is associated with systemic insulin resistance and increased apolipoprotein B/AI ratio in men and women. J Intern Med 2007, 262: 131-139.CrossRef Hoffstedt J, Forster D, Lofgren P: Impaired subcutaneous adipocyte lipogenesis is associated with systemic insulin resistance and increased apolipoprotein B/AI ratio in men and women. J Intern Med 2007, 262: 131-139.CrossRef
67.
go back to reference Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. Jama 2007, 298: 776-785.CrossRef Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D'Agostino RB, Vasan RS: Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. Jama 2007, 298: 776-785.CrossRef
68.
go back to reference Onat A, Can G, Hergenc G, Yazici M, Karabulut A, Albayrak S: Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes (Lond) 2007, 31: 1119-1125.CrossRef Onat A, Can G, Hergenc G, Yazici M, Karabulut A, Albayrak S: Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes (Lond) 2007, 31: 1119-1125.CrossRef
69.
go back to reference Rasouli M, Kiasari AM: Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease. Clin Biochem 2006, 39: 971-977.CrossRef Rasouli M, Kiasari AM: Interactions of serum hsCRP with apoB, apoB/AI ratio and some components of metabolic syndrome amplify the predictive values for coronary artery disease. Clin Biochem 2006, 39: 971-977.CrossRef
70.
go back to reference Sierra-Johnson J, Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Gami AS, Lopez-Jimenez F: Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006, 98: 1369-1373.CrossRef Sierra-Johnson J, Somers VK, Kuniyoshi FH, Garza CA, Isley WL, Gami AS, Lopez-Jimenez F: Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am J Cardiol 2006, 98: 1369-1373.CrossRef
71.
go back to reference Walldius G, Jungner I: The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 2006, 259: 493-519.CrossRef Walldius G, Jungner I: The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 2006, 259: 493-519.CrossRef
72.
go back to reference Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364: 937-952.CrossRef Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364: 937-952.CrossRef
Metadata
Title
Enhancement of a modified Mediterranean-style, low glycemic load diet with specific phytochemicals improves cardiometabolic risk factors in subjects with metabolic syndrome and hypercholesterolemia in a randomized trial
Authors
Robert H Lerman
Deanna M Minich
Gary Darland
Joseph J Lamb
Barbara Schiltz
John G Babish
Jeffrey S Bland
Matthew L Tripp
Publication date
01-12-2008
Publisher
BioMed Central
Published in
Nutrition & Metabolism / Issue 1/2008
Electronic ISSN: 1743-7075
DOI
https://doi.org/10.1186/1743-7075-5-29

Other articles of this Issue 1/2008

Nutrition & Metabolism 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.